SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following its latest financial results, where a reported earnings beat is being largely overshadowed by weak forward guidance, fueling widespread debate among investors. The community is sharply divided, with many anticipating further declines due to competitive pressures and supply concerns, while a segment emphasizes the company's long-term strategic transformation and government support in the evolving AI sector.

Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1999 and is headquartered in Rockville, MD.

Sensei Biotherapeutics Inc

Sensei Biotherapeutics (SNSE) is trending due to widespread community anticipation of a significant short squeeze, fueled by its extremely low public share float. Discussions center on trapped shorts and strong buying interest, with many accumulating positions in a belief that the company's cash-rich balance sheet and ongoing strategic review make it primed for a substantial upward move. The excitement reflects a broader trend of rapid gains seen in other micro-cap stocks.

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Altimmune Inc

Altimmune Inc. is trending strongly, driven by widespread community speculation regarding a potential buyout following its recent FDA Breakthrough Therapy Designation for pemvidutide in MASH. Investors are actively discussing significant positive price action, unusual after-hours volume, and the company's position within the lucrative GLP-1 and MASH treatment sector, anticipating further upward momentum.

Advanced Micro Devices, Inc. engages in the provision of semiconductor businesses. It operates through the following segments: Data Center, Client, Gaming, and Embedded. The Data Center segment includes server-class CPUs, GPUs, AI accelerators, DPUs, FPGAs, SmartNICs, and Adaptive SoC products. The Client segment refers to the computing platforms, which are a collection of technologies that are designed to work together to provide a more complete computing solution. The Gaming segment is a fundamental component across many products and can be found in APU, GPU, SoC or a combination of a discrete GPU with another product working in tandem. The Embedded segment focuses on the embedded CPUs, GPUs, APUs, FPGAs, and Adaptive SoC products. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

Advanced Micro Devices is trending as competitor Intel's recent disappointing outlook fuels community discussion about significant market share shifts within the semiconductor industry. Investors are highly bullish on AMD, pointing to its strong position in AI-driven data center and server demand, alongside an anticipated CPU shortage, as key drivers for its continued growth and potential to reach new highs.

Ascent Solar Technologies, Inc. engages in the design, development, and manufacture of solar technology and power solutions for remote locations and extreme environments. It integrates photovoltaic modules into a variety of applications such as aerospace, defense, transportation, and electronic products. The company was founded by Mohan S. Misra and Joseph H. Armstrong on October 18, 2005 and is headquartered in Thornton, CO.

Ascent Solar Technologies Inc

Ascent Solar Technologies is trending on news of strategic partnerships and ambitious 2026 goals, highlighting its specialized flexible solar technology for the burgeoning space and defense industries. Community discussion is amplified by connections to Elon Musk's recent comments on solar-powered AI satellites and the presence of a former SpaceX founder on ASTI's board, fueling speculation about significant upside potential and short squeeze plays despite past dilution concerns.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares ETF (GLD) is a major talking point as it rallies near record highs, with recent geopolitical concerns, particularly around European tariffs and Greenland, sparking considerable debate. The community is split, with bulls pointing to persistent global instability and central bank buying as drivers, while bears caution against an overheated market, alleging manipulation and expecting a significant pullback, despite a recent analyst target hike to $5,400.

Movano, Inc. is a health-focused technology company. The firm uses non-invasive technology to enable individuals and their healthcare partners to measure and manage their health conditions. It offers solutions through the app, the cloud, the wearable, and the sensor. The company was founded by Michael Aaron Leabman in January 2018 and is headquartered in Pleasanton, CA.

Movano Inc

Movano Inc. is trending amid news of its merger with AI cloud firm Corvex, which has secured a long-term NVIDIA H200 GPU deployment. This has ignited debate among traders, with bulls anticipating a short squeeze fueled by the low float and AI narrative, while others express skepticism over potential dilution and the actual nature of the NVIDIA involvement.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is experiencing significant attention following its complete acquisition of Texas Critical Data Centers and a strategic partnership with Primary Digital Infrastructure to co-develop a 1+ gigawatt hyperscale AI data center campus. The community is actively speculating on a forthcoming anchor tenant announcement, with many anticipating substantial long-term growth as NUAI positions itself to power next-generation computing, despite ongoing discussions around potential dilution and short interest.

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. Its product Arakoda helps in the prevention of malaria. The company was founded by Geoffrey Dow on September 9, 2010 and is headquartered in Washington, DC.

60 Degrees Pharmaceuticals Inc

60 Degrees Pharmaceuticals is trending due to its announced partnership with Runway Health, aiming to expand access to its FDA-approved malaria prevention drug, ARAKODA, via a telehealth platform. This news has fueled significant speculative trading, with many discussing a potential short squeeze given its low float and drawing comparisons to other recent volatile movers.

Movement Network is a secure and scalable blockchain designed to make Move programming accessible to developers everywhere. With high-performance execution and security, Movement delivers the infrastructure for the next generation of decentralized applications and unleashes opportunity and financial empowerment for anyone, anywhere.  $MOVE is the native token of Movement Network, for transaction fees and staking to secure the network. The Movement M1 (Layer 1) Network is powered by the Move programming language, unleashing opportunity, accessibility, and financial empowerment for anyone, anywhere.

MarketMove

MarketMove (MOVE CRYPTO) is trending following its recent listings on major exchanges, driving significant trading volume and community discussion. Investors are actively debating its potential for rapid price appreciation, with many highlighting its advanced MoveVM technology and comparisons to established blockchains like Sui and Solana. While some users express concerns about recent volatility, bullish sentiment persists, anticipating substantial growth as the project expands within the decentralized finance ecosystem.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q2 EPS Estimate for Agios Pharmaceuticals Boosted by Analyst

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Analysts at Zacks Research boosted their Q2 2026 earnings per share (EPS) estimates for shares of Agios Pharmaceuticals in a research report...

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twelve research firms that are presently covering the firm, Marketbeat...

Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO). In a filing disclosed on January 12th, the Representative disclosed that...

Agios Pharmaceuticals Touts 2026 Growth Plan at JPM: Acvezmi Launch, SCD Data, Expense Discipline

Agios Pharmaceuticals (NASDAQ:AGIO) used its presentation at the 44th Annual J.P. Morgan Healthcare Conference to outline its outlook for 2026, highlighting a new thalassemia launch, continued...

JPMorgan Chase & Co. Boosts Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $25.00

JPMorgan Chase & Co. raised their price objective on Agios Pharmaceuticals from $20.00 to $25.00 and gave the stock a "neutral" rating in a report on Tuesday...

Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells 2,932 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CFO Cecilia Jones sold 2,932 shares of the stock in a transaction that occurred on Tuesday, December 30th. The stock was sold at an average...

Agios Pharmaceuticals (NASDAQ:AGIO) CFO Sells $79,427.88 in Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CFO Cecilia Jones sold 2,932 shares of the company's stock in a transaction dated Tuesday, December 30th. The shares were sold at an...

Insider Selling: Agios Pharmaceuticals (NASDAQ:AGIO) Insider Sells 2,932 Shares of Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider Tsveta Milanova sold 2,932 shares of the company's stock in a transaction dated Tuesday, December 30th. The stock was sold at an...

Agios Pharmaceuticals (NASDAQ:AGIO) CEO Brian Goff Sells 18,703 Shares

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) CEO Brian Goff sold 18,703 shares of the stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average...

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3% - Should You Sell?

Agios Pharmaceuticals (NASDAQ:AGIO) Shares Down 5.3% - Time to Sell...

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Policy uncertainty from Trump

Earnings & guidance

Options / dealer positioning

Liquidity & algos

Markets are reacting to a mix of policy headlines, earnings, and positioning. We want to hear what you think is driving volatility the most right now.

What&#39;s the biggest driver of market volatility right now?

Stocktwits

What's the biggest driver of market volatility right now?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$1.95	--	--	N/A
Q3 '25	-$1.90	-$1.78	6.14%	BEAT
Q2 '25	-$1.81	-$1.93	-6.78%	MISSED
Q1 '25	-$1.77	-$1.55	12.46%	BEAT
Q4 '24	-$1.70	-$1.44	15.24%	BEAT

AGIO
Agios Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest AGIO News

AGIOAgios Pharmaceuticals Inc